BioScrip (NASDAQ:BIOS) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Thursday.

A number of other analysts have also recently commented on the stock. Zacks Investment Research cut shares of BioScrip from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. SunTrust Banks reiterated a “buy” rating and issued a $3.00 price target on shares of BioScrip in a research note on Friday, November 3rd. BidaskClub cut shares of BioScrip from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. Finally, Jefferies Group reiterated a “buy” rating and issued a $4.00 price target (up previously from $3.00) on shares of BioScrip in a research note on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. BioScrip presently has a consensus rating of “Hold” and an average price target of $3.60.

Shares of BioScrip (BIOS) opened at $2.54 on Thursday. The company has a debt-to-equity ratio of -6.11, a current ratio of 1.91 and a quick ratio of 1.60. BioScrip has a 12 month low of $0.98 and a 12 month high of $3.39.

BioScrip (NASDAQ:BIOS) last announced its quarterly earnings results on Thursday, November 2nd. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). The business had revenue of $198.70 million for the quarter, compared to analysts’ expectations of $202.91 million. BioScrip’s revenue was down 11.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.12) EPS. analysts expect that BioScrip will post -0.63 EPS for the current fiscal year.

In related news, CEO Daniel E. Greenleaf acquired 15,000 shares of the company’s stock in a transaction dated Thursday, November 9th. The shares were bought at an average cost of $2.03 per share, with a total value of $30,450.00. Following the completion of the transaction, the chief executive officer now directly owns 31,000 shares of the company’s stock, valued at $62,930. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michael G. Bronfein sold 27,000 shares of the stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $2.69, for a total transaction of $72,630.00. Following the completion of the transaction, the director now directly owns 129,669 shares in the company, valued at $348,809.61. The disclosure for this sale can be found here. 0.80% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Dynamic Technology Lab Private Ltd bought a new position in shares of BioScrip in the third quarter valued at about $114,000. Captrust Financial Advisors bought a new position in shares of BioScrip in the second quarter valued at about $123,000. Voya Investment Management LLC raised its position in shares of BioScrip by 41.4% in the second quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock valued at $138,000 after purchasing an additional 14,867 shares during the period. Highbridge Capital Management LLC bought a new position in shares of BioScrip in the third quarter valued at about $153,000. Finally, Goldman Sachs Group Inc. raised its position in shares of BioScrip by 65.8% in the first quarter. Goldman Sachs Group Inc. now owns 64,257 shares of the company’s stock valued at $109,000 after purchasing an additional 25,500 shares during the period. 84.44% of the stock is currently owned by institutional investors.

WARNING: “BioScrip (BIOS) Stock Rating Upgraded by ValuEngine” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/12/02/bioscrip-bios-stock-rating-upgraded-by-valuengine.html.

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Receive News & Stock Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related stocks with our FREE daily email newsletter.